Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance

References

• Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181–91.
   Google Scholar
• Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. Lancet 2007;370:685–97.
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745–9.
   PubMed Web of Science ®Google Scholar
• Joshi B, Mukherjee S, Patil A, et al. A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India. Indian J Endocr Metab 2014;18:317–24.
   PubMedGoogle Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.
   Web of Science ®Google Scholar
• Wajchenberg BL, Achando SS, Okada H, et al. Determination of the source(s) of androgen overproduction in hirsutism associated with polycystic ovary syndrome by simultaneous adrenal and ovarian venous catheterization. Comparison with the dexamethasone suppression test. J Clin Endocrinol Metab 1986;63:1204–10.
   PubMed Web of Science ®Google Scholar
• Axelrod LR, Goldzieher JW. The polycystic ovary. III. Steroid biosynthesis in normal and polycystic ovarian tissue. J Clin Endocrinol Metab 1962;22:431–40.
   PubMed Web of Science ®Google Scholar
• Rittmaster RS, Thompson DL. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab 1990;70:1096–102.
   PubMed Web of Science ®Google Scholar
• Barnes RB, Rosenfield RL, Burstein S, et al. Pituitary-ovarian responses tonafarelin testing in the polycystic ovary syndrome. N Engl J Med 1989;320:559–65.
   PubMed Web of Science ®Google Scholar
• Gilling-Smith C, Story H, Rogers V, et al. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol 1997;47:93–9.
   PubMed Web of Science ®Google Scholar
• Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril 2010;93:1938–41.
   PubMed Web of Science ®Google Scholar
• Kumar A, Woods KS, Bartolucci AA, et al. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol 2005;62:644–9.
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes. J Endocrinol Invest 2007;30:111–16.
   PubMed Web of Science ®Google Scholar
• Amato MC, Galluzzo A, Merlino S, et al. Lower insulin sensitivity differentiates hirsute from non-hirsute Sicilian women with polycystic ovary syndrome . Eur J Endocrinol 2006;155:859–65.
   PubMed Web of Science ®Google Scholar
• Lerchbaum E, Schwetz V, Giuliani A, et al. Opposing effects of dehydroepiandrosteronesulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil Steril 2012;98:1318–25.
   PubMed Web of Science ®Google Scholar
• Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113–16.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–9.
   PubMed Web of Science ®Google Scholar
• Poretsky L, Smith D, Seibel M, et al. Specific insulin binding sites in human ovary. J Clin Endocrinol Metab 1984;59:809–11.
   PubMed Web of Science ®Google Scholar
• Barbieri RL, Makris A, Ryan KJ. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol 1984;64:73S–80S.
   PubMed Web of Science ®Google Scholar
• Prelevic GM. Insulin resistance in polycystic ovary syndrome. Curr Opin Obstet Gynecol 1997;9:193–201.
   PubMed Web of Science ®Google Scholar
• Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update 2012;18:618–37.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006;91:4237–45.
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7.
   PubMed Web of Science ®Google Scholar
• Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Physiology and pathology of the female reproductive axis. In: Bulun S, E, editors. William's textbook of endocrinology. Philadelphia (PA): Elesveir; 2011. p. 581–818.
   Google Scholar
• Borruel S, Fernández-Durán E, et al. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2013;98:1254–63.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Sanchón R, San Millán JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008;93:527–33.
   PubMed Web of Science ®Google Scholar
• Boyle JA, Cunnigham J, O'Dea K, et al. Prevalence of polycystic ovary syndrome in a sample of Indigenous women in Darwin, Australia. Med J Aust 2012;196:62–6.
   PubMed Web of Science ®Google Scholar
• Rosenfield RL. Clinical review: Adolescent anovulation: maturational mechanisms and implications. J Clin Endocrinol Metab 2013;98:3572–83.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care 2015;38:S1–S94.
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–19.
   PubMed Web of Science ®Google Scholar
• DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83:1454–60.
   PubMed Web of Science ®Google Scholar
• Silfen ME, Denburg MR, Manibo AM, et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003;88:4682–8.
   PubMed Web of Science ®Google Scholar
• Plymate SR, Matej LA, Jones RE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988;67:460–4.
   PubMed Web of Science ®Google Scholar
• Moran C, Arriaga M, Arechavaleta-Velasco F, et al. Adrenal androgen excess and body mass index in polycystic ovary syndrome. J Clin Endocrinol Metab 2015;100:942–50.
   PubMed Web of Science ®Google Scholar
• Brennan K, Huang A, Azziz R. Dehydroepiandrosteronesulfate and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 2009;91:1848–52.
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab Clin Exp 1994;43:647–54.
   PubMed Web of Science ®Google Scholar
• Vaikkakara S, Al-Ozairi E, Lim E, et al. The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. Gynecol Endocrinol 2008;24:87–92.
   PubMed Web of Science ®Google Scholar